AI Article Synopsis

  • The study compares two treatment approaches for advanced ovarian, tubal, and peritoneal cancers: primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT), finding that NACT may not be as effective as PDS for overall survival (OS).
  • A total of 301 patients were randomized, with median OS of 49.0 months for PDS and 44.3 months for NACT, illustrating that while NACT is less invasive, it did not confirm noninferiority compared to PDS.
  • Factors like tumor resection success and patient characteristics influenced outcomes; thus, while NACT may be effective, further examination is needed to determine if it can broadly replace PDS in treatment

Article Abstract

Background: Regarding the comparison between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) for stage III/IV ovarian, tubal and peritoneal cancers, EORTC55971 and CHORUS studies demonstrated noninferiority of NACT. Previously, we reported reduced invasiveness of NACT in JCOG0602. This is a final analysis including the primary endpoint of overall survival (OS).

Methods: Patients were randomised to PDS (PDS followed by 8x paclitaxel and carboplatin, i.e. TC regimen) or NACT (4x TC, interval debulking surgery [IDS], 4x TC). The primary endpoint was OS. The noninferiority hazard ratio (HR) margin for NACT compared with PDS was 1·161. The planned sample size was 300.

Findings: Between 2006 and 2011, 301 patients were randomised, 149 to PDS and 152 to NACT. The median OS was 49·0 and 44·3 months in the PDS and NACT. HR for NACT was 1·052 [90·8% confidence interval (CI) 0·835-1·326], and one-sided noninferiority p-value was 0·24. Median progression-free survival was 15·1 and 16·4 months in the PDS and NACT (HR: 0·96 [95%CI 0·75-1·23]). In the PDS arm, 147/149 underwent PDS and 49/147 underwent IDS. In the NACT arm 130/152 underwent IDS. Complete resection was achieved in 12% (17/147) of PDS and 31% (45/147) of PDS ± IDS in the PDS arm and in 64% (83/130) of IDS in the NACT arm. Optimal surgery (residual tumour <1 cm) was achieved in 37% (55/147), 63% (92/147), and 82% (107/130 respectively. In the NACT, PS 2/3, serum albumin ≤2·5, CA125 > 2000 an institution with low study activity was advantageous, whereas clear/mucinous histology was disadvantageous for OS.

Interpretation: The noninferiority of NACT was not confirmed. NACT may not always be a substitute for PDS. However, as our study had smaller numbers, the noninferiority of the previous studies cannot be denied.

Funding: Ministry of Health, Labour and Welfare, Japan and the National Cancer Center, Japan.

Clinical Trial Information: UMIN000000523.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.02.020DOI Listing

Publication Analysis

Top Keywords

nact
13
debulking surgery
12
pds
12
primary debulking
8
neoadjuvant chemotherapy
8
stage iii/iv
8
iii/iv ovarian
8
ovarian tubal and
8
tubal and peritoneal
8
peritoneal cancers
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!